Day 4 ASCO 2021 Roundup: Immunotherapy Candidates Show Promise in Early Studies
The fourth day of the ASCO 2021 virtual annual meeting featured clinical trial data of some promising immunotherapy candidates.
Oncolytic Viral Therapy Shows Promising Results in Fighting T-cell Lymphoma. Joselle Cook, MBBS, from the Mayo Clinic presented the results of Phase 1 clinical trial testing the effects of a novel oncolytic virotherapy against hematological malignancies.
It's free! Log in now to read
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03